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Summary.-In a retrospective analysis of 87 cases of Caucasian childhood non-
Hodgkin malignant lymphoma (NHML) from Lyon, France, all the case were
diffuse lymphomas, but 47 were diagnosed as monomorphic small non-cleaved
NHML, pathologically indistinguishable from Burkitt's lymphoma (BL). BL could
then be the most frequent childhood lymphoma in France.
This homogeneous series allows better definition of the characteristics of BL
within NHML.
Age distribution is similar to that of endemic BL, with a sex ratio of 3.7/1.
Abdominal masses are initially present in 68% of the cases, whereas jaw is in-
volved in only 4%.
The disease is characterized by its overwhelming evolution in the absence of
therapy. However, complete remission (CR) is usually obtained after the first chem-
therapy regimen. Most relapses occur at 3-8 months. Death could be related to
cerebrospinal fluid (CSF) involvement, local recurrence or secondary marrow
involvement. Ninety per cent of the patients alive with no evidence of disease (NED)
8 months after CR can be considered as definitely cured.
Our study on Caucasian children with NHML indicates that, from histological
and clinical criteria, nearly half the cases are very similar to African BL. Even
though EBV rarely associated with our cases, BL could be a worldwide lymphoma.
CONFUSION AND CONTROVERSY persist
with regard to the eponym "Burkitt's
lymphoma" (BL) which was used initially
to refer to a clinical and epidemiological
entity in African children (Burkitt, 1958,
1962). Burkitt's initial report described a
tumour "involving the jaw in African
children" and "dependent on climatic
factors" and suggested "the implication
of an infectious agent in its aetiology"
(Burkitt, 1958, 1962). In 1964, Epstein
et al. first described, in a cultured Burkitt-
cell line, the herpes-type virus now known
as the Epstein-Barr virus (EBV). In
tropical Africa and in New Guinea,
96-97% of cases are associated with EBV
(see: Klein, 1975; IARC, 1981) and
African endemic BL (EBL) is now recog-
nized as a clear epidemiological entity.
The question whether this lymphoma is
unique and restricted to endemic regions
of the world, or whether it can also be
found elsewhere, arose with 3 reports in
1965-1966 (Dorfman, 1965; O'Conor et al.,
1965; Wright, 1966). The answer should
have been provided by the plethora of
reports from many countries, published
between 1966 and 1970 (see: Philip et al.,
1980b; Lenoir et al., unpublished). How-
ever, there was a tendency to contrast
EBL with BL arising outside Africa
(non-endemic BL), the latter being spora-
dic, mainly abdominal in presentation,
andusuallynot EBV-associated (Dorfman,BURKITT-TYPE LYMPHOMA IN FRANCE
1965; Cohen et al., 1969; Hirshaudt et al.,
1973; Ablashi et al., 1974; Levine & Cho
1974; Banks et al., 1975).
The confusion and controversy existed
because most of the reports did not take
into consideration the clear conclusions
formalized in 1969 by a World Health
Organization expert committee (Berard
et al., 1969). The committee carried out a
detailed and objective study of cases
gathered from Africa and other countries,
and concluded that BL is a clear, patho-
logical entity which is found all over the
world and has features distinct from those
of other undifferentiated lymphomas and
leukaemias. It recommended that the
tumour be referred to as a "malignant
lymphoma undifferentiated Burkitt type".
In large series of childhood non-
Hodgkin malignant lymphomas (NHML)
outside the endemic region, BL was
reported to account for from 0% (Wollner
et al., 1980) to 45.6% (Gerard-Marchant
et al., 1982).
The purpose ofour study was to conduct
a retrospective analysis of 87 cases of
NHML in children. Two of us (RGM and
PAB) were asked to identify cases to
which the WHO definition ofBL could be
applied; and we report here 47 cases ofBL
found in Caucasian children from Lyon,
France, between 1965 and 1979. This
homogeneous series makes it possible to
define epidemiological and clinical features
of BL in France. We hope that these data
will stimulate new pathological studies of
previously reported series, since BL ap-
pears to be a clear clinico-pathological
entity within childhood NHML.
MATERIAL AND METHODS
Between 1965 and 1979, 146 patients
under 16 years ofage were treated for NHML
at the Centre Leon Berard, Lyon (75 patients)
and at other chemotherapy units in Lyon
(71 patients). Since 36 cases with incomplete
clinical records were excluded, 110 were
reviewed (Philip et al., 1980b). Non-Caucasian
cases and patients for whom initial sections
were not available were also left out; thus
our analysis was finally carried out on 87
Caucasian patients. Sections were reexam-
ined for 76 patients (average of 3 stained
sections from each patient) and new sections
were available for 11 cases (at least 7 sections
per patient). Sections routinely stained with
haematoxylin and eosin and embedded in
paraffin were thus available for all the cases.
New sections were stained with haematoxy-
lin and eosin, periodic-acid-Schiff, May-
Griinwald-Giemsa, Wilder silver reticulin
impregnation and Giemsa by the Lennert
technique.
Histological data.-Histological material
from all 87 cases before treatment was
reviewed independently by 2 of us, without
knowledge of the clinical data.
R.G.M. reviewed the cases using the Kiel
classification (Gerard-Marchant et al., 1974).
Details of this classification in childhood
NHML are given in Table I. P.A.B. reviewed
the cases using a modification of the Rappa-
port classification (Bryon et al., 1981).
TABLE I.-Classification of non-Hodgkin's
malignant lymphoma in children accord-
ing to the Kiel classification and the
personal experience of R.G.M.
Lymphoblastic
Burkitt-type
With convoluted nuclei
Others
Immunoblastic
Pure
Immunoplasmoblastic
Other
Epithelioid
Lymphoplasmocytoid
Reticulosarcoma
Unclassified
TABLE II.-Classification ofnon-Hodgkin's
malignantlymphomainchildrenaccording
to the personal classification of P.A.B.
(a modification of Rappaport's classifi-
cation).
Lymphoblastic
With convoluted nuclei
Without convoluted nuclei
Burkitt-type
Typical monomorphic, small non-cleaved
Monomorphic, small non-cleaved with larger cells
Histiocytic (diffuse, large cells)
Non-cleaved (immunoblastic)
Cleaved
Mixed
Blastic
Unclassified
671T. PHILIP ET AL.
TABLE III.-Clinical staging systems used in the present study
Stage I
Murphy Single tumour (extra-nodal)
or single anatomic area
(nodal), with the
exclusion ofmediastinum
or abdomen.
Stage A
Ziegler Single extra-
abdominal site
II
Single tumour (extra-
nodal) with regional
node involvement.
Two or more nodal areas
on the same side ofthe
diaphragm.
Two single (extranodal)
tumours with or
without regional node
involvement on the
same side ofthe
diaphragm
A primary gastro-
intestinal-tract
tumour, usually
ileocaecal, with or
without involvement
of associated
mesenteric nodes only.
AR B
Intra-abdominal Multiple extra-
tumour with abdominal sites
>90%
surgically
resected.
III
Two single tumours
(extra-nodal) on
opposite sides of
the diaphragm.
Two or more nodal
areas above and
below the diaphragm.
All the primary
intrathoracic
tumours.
All extensive primary
intra-abdominal
disease.
All paraspinal or
epidural tumours.
C
Intra-abdominal
tumour
IV
Any tumours
already
mentioned with
initial CNS
and/or marrow
involvement.
D
Intra-abdominal
tumour with
involvement of
> 1 extra-
abdominal site.
Details of this classification for children are
given in Table II.
Cases over which there was disagreement
were reexamined, when complete clinical
and follow-up information was made avail-
able to the pathologists. When both review-
ers agreed onthediagnosis ofBL, the case was
included in the final series.
Clinical data.-The cases considered to be
BL were first studied on the basis of a
complete pretreatment evaluation, i.e., com-
plete blood count, measurements of serum
urea, uric acid, electrolytes, serum lactic
dehydrogenase, bilirubin, alkaline phospha-
tase and transaminase, marrow aspirate
(1-4 per patient. average 2), urine analysis,
i.v. pyelogram, chest roentgenograms, exam-
ination of cerebrospinal fluid for malignant
cells andprotein, and careful clinical examina-
tion.
Staging was done using Murphy (1977)
and Ziegler (1977) classifications (Table III).
In cases of localized BL (Murphy, Stages I
and II; Ziegler, Stages A and AR) lympho-
graphy has been performed since 1975 to
avoid errors of staging.
Before 1973, patients were treated with
radiotherapy at the initial site and with a
mono- or bi-chemotherapeutic regimen (cyclo-
phosphamide and vincristine) for 2 years (33
patients). After 1973, patients were treated
with polychemotherapy (Gout-Lemerle et al.,
1976), with a combination of cyclophospha-
mide, vincristine, prednisone and adriamycin
(COPAD) (14 patients). Patients were judged
to be in complete remission (CR) if there was
no clinically palpable tumour and if all
previously abnormal parameters had returned
to normal. Survival curves, using the 2
staging classifications, were calculated by
the method of Kaplan and Meier (1958).
RESULTS
Histopathology
The 2 pathologists examining histo-
logical material without knowledge of the
clinical data agreed over 71/87 cases
(81-6%); they agreed initially that 43 of
these 71 were BL.
Results of the second review (in the
light of clinical data and of the other
reviewer's opinion) are summarized in
Table IV. Agreement was reached to
discard 4 cases that were not considered
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TABLE IV.-Study of 87 non-Hodgkin malignant lymphomas: distribution of histopatho-
logical types according to 2 reviewers (final opinion)
Kiel classification (R.G.M.)
Lymphoblastic
Burkitt-type
Lymphoblastic
with convoluted nuclei
without convoluted nuclei
Immunoblastic
Unclassified
Not NHML
Total of87: Final agreement 83/87 9}
(of total
Total of 83)
Modification ofRappaport's
classification (P.A.B.)
51 61*4 Burkitt-type
Lymphoblastic
14 16*9 with convoluted nuclei without convoluted nuclei
4 4- 8 Histiocytic
non-cleaved
mixed
14 16*9 Unclassified
4 Not NHML
5.4%.
(oftotal
Total of83)
47 56 a6
5l if
18*1
7*2
18.1
6
15
4
to be NHML (the percentages are thus
calculated on the basis of the 83 cases of
confirmed NHML) and to consider the
83 remaining cases as diffuse lymphomas.
With regard to the 4 cases on which there
was final disagreement, they were con-
sidered as BL by R.G.M., and as lympho-
blastic non-convoluted, histiocytic non-
cleaved, mixedhistiocytic, andunclassified
by P.A.B.
The data can be summarized as follows:
(1) After discussion, 47 cases were
diagnosed as BL. The 2 pathologists
agreed that, in Giemsa-stained sections,
BL is a diffuse lymphoma composed of
monomorphic lymphoid cells of uniform
maturity with a round nucleus and 3-4
nucleoli; they have a moderate amount of
cytoplasm, which is well defined, deeply
basophilic and usually contains clear
vacuoles.
(2) One of us (P.A.B.), using a histo-
morphometric technique (Bryon et al.,
1981), identified 2 types of cell in the BL
group: 30 cases with a typical, mono-
morphic, small non-cleaved cell, and 17
cases with a slightly larger cell. No
differences were found between the 2
groups with regard to age, staging,
initial presentation or survival (Philip
et al., 1980b).
Clinical data
The results obtained from the 47 cases
are summarized in Figs. 1-4, and Tables V
and VI.
Sex and age distribution
There were 37 males and 10 females
among thepatients (ratio 3.7: 1).
The age distribution of the patients is
given in Fig. 1, indicating a peak incidence
betweentheagesof6and 9(18/47patients).
The distribution between 21 and 16 years
shows an average for the whole group of
8-5 years.
Initial presentation
As shown in Table V, by far the most
frequent site at presentation (in 68% of
cases, 32 patients) was the abdomen.
Lymph-node involvement was seen ini-
tially in 9 patients (19.1%) (7 with head
TABLE V.-Site of initial presentation and stage (Murphy classification) in 47 cases of
Burkitt's lymphoma in Caucasian patients
Site Stage
A A ,
Abdomen Lymph nodes Subcutaneous Intracranial Jaw I II III IV
No. 32 9 2 2 2 7 7 26 7 % 68 19.1 4-3 4-3 4.3 14*9 14-9 55-3 14-9
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TABLE VI.-Sites ofrelapsefinally responsiblefor death in 28 cases (19 are alive NED)
First site of relapse
or progression
Cerebrospinal fluid
Local recurrence
Marrow involvement
Other sites
Other causes ofdeath
(at induction of
therapy)
Follow-up in months
0 1
0
0
2 3 4 5 6 7 8
0
0
0
0
0
0
0
0
0
0
lymph
node
9 10 11 12 16
* . -
0 0
0 0
0
chest
0
(16 months)
0
0
0
0
presented initially with marrow involve-
ment (5-25% of Burkitt cells in marrow
smears). This group clearly had a bad
prognosis with both staging systems (cf.
Figs. 2 & 3).
IL
FIG. 1.-Age distribution of the 47 cases of
Burkitt's lymphoma.
and neck localization) and other sites in
6 patients; viz. s.c. (2), intracranial (2),
and jaw (2). Jaw localization thus ac-
counted for only 4.3% of the cases in 2
boys (71 and 8 years old).
Staging
Two major classifications made it pos-
sible to distinguish 2 groups of patients.
Localized disease (Murphy Stages I and II,
Ziegler Stages A and AR) was seen
initially in 14 patients (29.8%). This
group of patients clearly has a good
prognosis in both staging systems (c.f.
Figs. 2 & 3). Extensive disease (Murphy
Stages III and IV; Ziegler Stages C and D)
was seen initially in 33 patients (70.2%);
7 of these (14.8% of 47 patients) had
FIG. 2. Percentage survivors typed by the
Murphy classification * under treatment
Non Evidence of Disease (NED); 0, out of
treatment NED; A, alive under treatment
in 2nd CR NED.
* * * 00~~~O 0 0 * 0000
STAGE A and AR
12 pal.ents
,_ 0 000
--S-TAGE
STAGE C 25 pat.ents
STAGE 7p3 ant
FIG. 3.-Percentages of survivors typed by
the Ziegler classification (Stage B, with only
2 patients, has been omitted). Symbols as in
Fig. 2.
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24 months after relapse. Patients alive
NED 8 months after CR, have a 90%
chance of complete cure.
DISCUSSION
*
_ 00 0 0 0 0
Our data show that Burkitt-type lym-
phoma (BL) is a clear pathological entity
within NHML in Caucasian children. Two
, of us, using different major classifications, i 2 3 4 agreed immediately on a diagnosis of BL
4.-Survival curve of all 47 cases of BL for 43/47 patients (> 90% of the final Symbols as in Fig. 2. series). BL accounted for 56.6% of our
83 cases. The fact that this value is
higher than in other series reported in the
literature (Garwicz et al., 1974: 19%-
reral points should be noted. Com- Sullivan, 1978: 25%-Cossman & Berard,
remission (CR) was not obtained for 1980: 33%-Meadows et al., 1980: 25%-
atients; 2 died immediately after Wollner et al., 1980: 0%-Gerard-Mar-
ry for biopsy; 2 died during the first chant, 1981: 45.6%) may resultprincipally
due to metabolic disturbances; and from the recruitment of our patients; i.e.
not respond to therapy. Ofthe whole from a regional cancer institute where
), 40.4% of the patients are still only solid tumours (never leukaemias)
(Fig. 4). When the 13 patients who are treated. Lymphoblastic or non-abdom-
ot go into remission are excluded, inal lymphomas in children frequently
3urvival of the remainder reaches present as leukaemias and are usually
h. Achievement of CR is thus a received by other hospitals in the area,
r factor for a good prognosis. whereas cases of BL, which is most
o kinds of relapse can occur during frequently a solid abdominal tumour, are
nent (Table VI). CSF involvement is usually sent to the Centre Leon Berard.
early complication, especially in It is quite surprising to read the recent
ats with extensive disease, and oc- report by Wollner et al. (1980) of 35
d in 6/29 cases at 1-4 months of abdominal lymphomas in children, indi-
tion. Later, there may be local cating that none of them was a BL. It is
rence (9/29) and secondary marrow our opinion that Berard's report that BL
vement (8/29). Other sites of relapse accounts for one third ofchildhood NHML
rare (1 in lymph nodes and 1 in the outside Africa (Cossmann & Berard, 1980)
). is more likely to be epidemiologically
e survival curve was very different correct than are our data. We (Lenoir
that of other NHML in children et al., unpublished) have found 635 cases
4). Most fatal relapses occurred of BL reported in the literature that
3 8 months of evolution even though should be considered to be non-endemic
of the patients who relapsed before BL. The present report represents 7% of
nths died later (1 after 20 months, the cases published in the literature. It is
er 4 years). Twenty patients were our opinion that most of the abdominal
with no evidence of disease (NED) lymphomas reported as "undifferentiated
niths after achieving CR, and 18 are lymphomas" by the classification of Rap-
clive and can be considered cured. paport, could be in fact true BL; our data
relapsed with marrow involvement are not exceptional, and BL must be
.d 32 months after diagnosis (Table distinguished pathologically from other
I is dead, and 1 is still alive NED abdominal NHML in children.
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These data also show that Burkitt-type
lymphoma is a clear clinical entity. The
age-incidence curve, which indicates a
peak before the age of 10 years, is similar
to that of the recent Olweny report from
Uganda (Olweny et al., 1980) and to other
reports from different parts of the world
(Lenoir et al., unpub.). The finding in the
present series that BL is mainly (68%) an
abdominal lymphoma confirms previous
reports from outside Africa (Dorfman,
1965; Hoogstraten, 1967; Arseneau et at.,
1975; Levine et al., 1982). Other initial
sites of presentation were also found,
especially lymph-node involvement, but
jaw tumours were found in only 2 cases,
whereas 72% of patients described in
Uganda showed a jaw swelling (Olweny
et al., 1980). There is thus a clear clinical
difference between African and non-
African BL. Nevertheless, BL should not
be a synonym for "jaw tumour", as
numerous authors have assumed, who
identified BL only when a jaw tumour
was present (Willemin et al., 1966; Cuevas
et al., 1976; Joncas & Rioux, 1977). This
assumption represented a major bias in
the diagnoses of the 625 cases cited above
(Lenoir et al., unpub).
From our data, the characteristics of
BL outside Africa are summarized in
Table VII. We have found that patients
alive NED 8 months after CR can be
considered to have a 90% chance of
complete cure. This short evolution sug-
gests that non-endemic BL could be used
as a model for therapeutic research. In our
opinion, such research should be carried
out primarily on the 3 principal sites of
complication (CSF, local recurrence and
marrow). One of the most interesting
avenues of research in BL is the use of
intensive chemotherapy followed by mar-
row autografts (Ziegler, 1977; Appelbaum
et al., 1978). Recent observations by our
group (unpublished) confirm the high
efficiency of this regimen even in patients
in a second CR.
BL is thus a clinico-pathological entity
in Caucasian children. It is also an
immunological entity; when 10 of our 47
cases were studied by immunological
methods, all tumour cells were found to be
B cells with surface immunoglobulins.
This finding is confirmed by all the data
in the literature (Mann et al., 1976). BL is
also a cytogenetic entity: in 4 ofour cases,
the tumour cells were studied by banding
techniques, and 3 translocations of (8;14)
and one variant translocation, t (8;22),
were found (Bertrand et al., 1981). The
8;14 translocation, initially reported in
African cases as a 14q+ (Manolov &
Manolova, 1972), has been found in most
non-endemic BLs (Zech et al., 1976). Two
variant translocations, t (2;8) and t (8;22),
were then described in both endemic and
non-endemic BL (Bernheim et al., 1981).
These translocations are now considered
to be a characteristic feature of BL in all
parts of the world. Finally, whereas 96%
of endemic cases are EBV-associated, an
association rate of only 10-20% was
found in this series (Philip et al., 1980a;
Lenoir, unpub.).
It must be emphasized that the present
study is strictly pediatric. Levine's studies
in the US (Levine et al., 1982) clearly
show that BL is not only a pediatric
lymphoma, and unpublished data by
members of our group confirm this
conclusion.
The only major differences apparent
between non-endemic and endemic BL
are the high incidence, the high rate of
EBV association and the high jaw-tumour
TABLE VII.-Summary of characteristics of non-endemic Burkitt-type lymphoma
1. In Western countries, BL represents at least one third of childhood NHML.
2. The primary site of the tumour is usually abdominal or pelvic.
3. The disease is characterized by acute evolution in the absence of therapy.
4. The immediate risk, especially for extensive disease, is CFS involvement.
5. The second risk is local recurrence or secondary marrow involvement.
6. The evolution of the disease is short, 90% of relapses being < 8 months from diagnosis.
7. Children alive NED after 12 months are probably cured.
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frequency of the latter. The relationship
between incidence and EBV association
should be considered to favour the role of
EBV in the pathogenesis of African BL.
Our report of 100% EBV association in
Arab Algerian children from a non-
endemic area may indicate, however, that
socio-economic level is more important
thanincidence orgeography as an explana-
tion of the EBV association (Philip et al.,
1980a).
BL is first and foremost a histopatho-
logically distinct lymphoma. A retro-
spective analysis should now be made of
large series of pathological specimens in
order to establish the actual incidence of
BL among childhood NHML. The term
"Burkitt-type lymphoma" should be used
in all classifications.
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